Logo
x

Search

Subscribe Now

daiichi sankyo

Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

Daiichi Sankyo Reports the sNDA Submission of Enhertu to Treat HER2 Low or Ultralow Metastatic Breast Cancer in Japan

  • October 4, 2024
Daiichi Sankyo’ Enhertu Gains the US FDA’s Breakthrough Therapy Designation to Treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Daiichi Sankyo’ Enhertu Gains the US FDA’s Breakthrough Therapy Designation to Treat HER2 Low or HER2 Ultralow Metastatic Breast C...

  • August 20, 2024
Daiichi Reports the EMA’s Validation of Application for Enhertu to treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

Daiichi Reports the EMA’s Validation of Application for Enhertu to treat HER2 Low or HER2 Ultralow Metastatic Breast Cancer

  • August 20, 2024
Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma

Daiichi Sankyo Reports the MHLW’s Approval of Ezharmia (Valemetostat Tosilate) To Treat Peripheral T-Cell Lymphoma

  • June 25, 2024
PharmaShots Weekly Snapshots (April 29 – May 03, 2024)

PharmaShots Weekly Snapshots (April 29 – May 03, 2024)

  • May 3, 2024
Daiichi Sankyo and AstraZeneca Report the P-III (DESTINY-Breast06) Study Data of Enhertu to Treat Breast Cancer

Daiichi Sankyo and AstraZeneca Report the P-III (DESTINY-Breast06) Study Data of Enhertu to Treat Breast Cancer

  • April 29, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.